Serum-soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies.
Serum-soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies.
复制标题
B 细胞淋巴增殖性恶性肿瘤中的血清可溶性白细胞介素 2 受体。
DOI：
--
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
H. Moutsopoulos
中科院分区：
文献类型：
--
作者：
Nicholas A. Pavlidis;M. Manoussakis;G. Germanidis;H. Moutsopoulos
研究人员测定了 53 名 B 细胞淋巴增殖性恶性肿瘤患者血清中可溶性白细胞介素 2 受体 (sIL-2R) 的水平，其中包括 31 名非霍奇金淋巴瘤 (NHL) 患者、16 名慢性淋巴细胞白血病 (CLL) 患者和 6 名多发性骨髓瘤患者。此外，还使用 40 名患有各种实体瘤的患者以及 53 名健康个体的血清样本作为对照。结果发现，与正常对照（207+/-17单位/ml）相比，NHL（平均值+/-平均值的标准误差2,327+/-320单位/ml）和CLL患者（2517+/-451单位/ml）的sIL-2R平均血清水平显着升高（P小于0.001）。当分析多发性骨髓瘤或实体瘤患者的血清 sIL-2R 水平时，没有观察到这种差异。血清sIL-2R水平与NHL和CLL患者的临床分期、B症状的存在以及疾病活动性密切相关。事实上，化疗反应后 sIL-2R 水平显着降低或正常化，而在许多患者中，sIL-2R 值甚至能够预测疾病复发。最后，无法证明与 NHL 患者的组织学分级相关。我们得出结论，血清 sIL-2R (1) 仅在 B-NHL 和 B-CLL 中升高，但在骨髓瘤患者中不升高；(2) 与肿瘤负荷相关；(3) 可作为监测患者治疗的有价值的肿瘤标志物。
The levels of soluble interleukin-2 receptors (sIL-2R) were determined in the serum of 53 patients with B-cell lymphoproliferative malignancies, including 31 patients with non-Hodgkin lymphomas (NHL), 16 with chronic lymphocytic leukemia (CLL), and 6 with multiple myeloma. In addition, serum samples from 40 patients with various solid tumors as well as from 53 healthy individuals were used as controls. It was found that the mean serum levels of sIL-2R were significantly increased (P less than 0.001) in NHL (mean +/- standard error of the mean 2,327 +/- 320 units/ml) and CLL patients (2517 +/- 451 units/ml) as compared to normal controls (207 +/- 17 units/ml). No such difference was observed when the serum sIL-2R levels of patients with multiple myeloma or solid tumors were analyzed. Serum sIL-2R levels were closely related to the clinical stage, the presence of B-symptoms, and the disease activity of patients with NHL and CLL. In fact, response to chemotherapy was followed by marked decrease or normalization of sIL-2R levels, while in a number of patients sIL-2R values were even able to predict disease relapse. Finally, no association with histologic grade in NHL patients, could be demonstrated. We conclude that serum sIL-2R (1) are increased only in B-NHL and B-CLL but not in myeloma patients, (2) are related to the tumor burden, and (3) can serve as a valuable tumor marker for the monitoring of patients treatment.
影响因子：
56.9
作者：
SMITH, KA
通讯作者：
SMITH, KA
高血清白细胞介素 2 受体水平与儿童非霍奇金淋巴瘤的晚期疾病和不良预后相关。
影响因子：
20.3
作者：
Pui,CH;Ip,SH;Kung,P;Dodge,RK;Berard,CW;Crist,WM;Murphy,SB
通讯作者：
Murphy,SB
DOI：
10.1073/pnas.83.24.9694
发表时间：
1986-12-01
影响因子：
11.1
作者：
TSUDO, M;KOZAK, RW;WALDMANN, TA
通讯作者：
WALDMANN, TA